---
schema_version: "secwatch.filing_event.v1"
accession: "0000879407-26-000045"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:22:39.545000+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license

## Summary
- Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).
- REDEMPLO launch: >400 prescriptions, ~180 patients shipped, ~30 new scripts/week, 85% APOC3-naive patients.
- Licensed ARO-PNPLA3 to Madrigal for $25M upfront, up to $975M milestones, tiered royalties (high-single to mid-teens).
- Raised $930M: $700M zero-coupon converts due 2032 (35% premium) and $230M stock at $64.50/sh.
- Obesity: ARO-INHBE combo -9.4% weight loss wk16 (vs -4.8%); ARO-ALK7 -88% mRNA knockdown, -14.1% visceral fat.

## SEC filing metadata
- accession: 0000879407-26-000045
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/0000879407-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/arwr-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879407-26-000045
- JSON: https://secwatch.observer/filing/0000879407-26-000045.json
- Plain text: https://secwatch.observer/filing/0000879407-26-000045.txt

## Source-grounded claims
- claim_id: b4cd0f6b0ab82622c1db7c6dbdd95dd0f81240e0
  claim: ARROWHEAD PHARMACEUTICALS, INC. reported financial results for fiscal 2026 second quarter ended March 31, 2026.
  evidence_excerpt: Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/0000879407-26-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.